Cubist Pharma (CBST) Cash Flow Statement

Click line-items for a historical chart and %

Net income
Depreciation and amortization	74.83M
Amortization and accretion of investments	5.28M
Amortization of debt discount and debt issuance costs	29.41M
Deferred income taxes	12.29M
Foreign exchange (gain) loss
Stock-based compensation	28.37M
Contingent consideration
Charge for company 401(k) common stock match
Accounts receivable	8.03M
Inventory	-17.34M
Prepaid expenses and other current assets	5.99M
Other assets
Accounts payable and accrued liabilities	-64.93M
Deferred revenue and other long-term liabilities
Total adjustments
Net cash provided by operating activities
Purchases of property and equipment	-21.07M
Purchases of investments
Proceeds from investments	431.9M
Net cash used in investing activities
Payment of contingent consideration	0
Issuance of common stock, net	33.06M
Excess tax benefit on stock-based awards	8.71M
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Effect of changes in foreign exchange rates on cash balances
Cash and cash equivalents at beginning of period	91.06M
Cash and cash equivalents at end of period	233.69M

Entities mentioned with CBST

View All Entities